FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156216923> ?p ?o ?g. }

• W2156216923 endingPage "R86" @default.
• W2156216923 startingPage "R86" @default.
• W2156216923 abstract "Fatigue is one of the most disabling symptoms associated with fibromyalgia that greatly impacts quality of life. Fatigue was assessed as a secondary objective in a 2-phase, 24-week study in outpatients with American College of Rheumatology-defined fibromyalgia.Patients were randomized to duloxetine 60-120 mg/d (N = 263) or placebo (N = 267) for the 12-week acute phase. At Week 12, all placebo-treated patients were switched to double-blind treatment with duloxetine for the extension phase. Fatigue was assessed at baseline and every 4 weeks with the Multidimensional Fatigue Inventory (MFI) scales: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity, and Reduced Motivation. Other assessments that may be associated with fatigue included Brief Pain Inventory (BPI) average pain, numerical scales to rate anxiety, depressed mood, bothered by sleep difficulties, and musculoskeletal stiffness. Treatment-emergent fatigue-related events were also assessed. Changes from baseline to Week 12, and from Week 12 to Week 24, were analyzed by mixed-effects model repeated measures analysis.At Week 12, duloxetine versus placebo significantly (all p < .05) reduced ratings on each MFI scale, BPI pain, anxiety, depressed mood, and stiffness. Improvement in ratings of being bothered by sleep difficulties was significant only at Weeks 4 and 8. At Week 24, mean changes in all measures indicated improvement was maintained for patients who received duloxetine for all 24 weeks (n = 176). Placebo-treated patients switched to duloxetine (n = 187) had significant within-group improvement in Physical Fatigue (Weeks 16, 20, and 24); General Fatigue (Weeks 20 and 24); Mental Fatigue (Week 20); and Reduced Activity (Weeks 20 and 24). These patients also experienced significant within-group improvement in BPI pain, anxiety, depressed mood, bothered by sleep difficulties, and stiffness. Overall, the most common (> 5% incidence) fatigue-related treatment-emergent adverse events were fatigue, somnolence, and insomnia.Treatment with duloxetine significantly improved multiple dimensions of fatigue in patients with fibromyalgia, and improvement was maintained for up to 24 weeks.ClinicalTrials.gov registry NCT00673452." @default.
• W2156216923 created "2016-06-24" @default.
• W2156216923 creator A5029091280 @default.
• W2156216923 creator A5043357294 @default.
• W2156216923 creator A5057857378 @default.
• W2156216923 creator A5087515595 @default.
• W2156216923 creator A5091578640 @default.
• W2156216923 date "2011-01-01" @default.
• W2156216923 modified "2023-10-14" @default.
• W2156216923 title "Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial" @default.
• W2156216923 cites W1984390535 @default.
• W2156216923 cites W1987088208 @default.
• W2156216923 cites W1991834652 @default.
• W2156216923 cites W1995358795 @default.
• W2156216923 cites W1998631853 @default.
• W2156216923 cites W2003239266 @default.
• W2156216923 cites W2011373308 @default.
• W2156216923 cites W2014727419 @default.
• W2156216923 cites W2021630340 @default.
• W2156216923 cites W2048218606 @default.
• W2156216923 cites W2049921039 @default.
• W2156216923 cites W2091238378 @default.
• W2156216923 cites W2120713232 @default.
• W2156216923 cites W2128447164 @default.
• W2156216923 cites W2133915381 @default.
• W2156216923 cites W2140760407 @default.
• W2156216923 cites W2141535552 @default.
• W2156216923 cites W2150481636 @default.
• W2156216923 cites W2154761159 @default.
• W2156216923 cites W2160051254 @default.
• W2156216923 cites W2165844418 @default.
• W2156216923 cites W2253364553 @default.
• W2156216923 doi "https://doi.org/10.1186/ar3359" @default.
• W2156216923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3218901" @default.
• W2156216923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21668963" @default.
• W2156216923 hasPublicationYear "2011" @default.
• W2156216923 type Work @default.
• W2156216923 sameAs 2156216923 @default.
• W2156216923 citedByCount "35" @default.
• W2156216923 countsByYear W21562169232012 @default.
• W2156216923 countsByYear W21562169232013 @default.
• W2156216923 countsByYear W21562169232014 @default.
• W2156216923 countsByYear W21562169232015 @default.
• W2156216923 countsByYear W21562169232016 @default.
• W2156216923 countsByYear W21562169232017 @default.
• W2156216923 countsByYear W21562169232018 @default.
• W2156216923 countsByYear W21562169232019 @default.
• W2156216923 countsByYear W21562169232020 @default.
• W2156216923 countsByYear W21562169232021 @default.
• W2156216923 countsByYear W21562169232022 @default.
• W2156216923 countsByYear W21562169232023 @default.
• W2156216923 crossrefType "journal-article" @default.
• W2156216923 hasAuthorship W2156216923A5029091280 @default.
• W2156216923 hasAuthorship W2156216923A5043357294 @default.
• W2156216923 hasAuthorship W2156216923A5057857378 @default.
• W2156216923 hasAuthorship W2156216923A5087515595 @default.
• W2156216923 hasAuthorship W2156216923A5091578640 @default.
• W2156216923 hasBestOaLocation W21562169231 @default.
• W2156216923 hasConcept C118552586 @default.
• W2156216923 hasConcept C126322002 @default.
• W2156216923 hasConcept C142724271 @default.
• W2156216923 hasConcept C168563851 @default.
• W2156216923 hasConcept C1862650 @default.
• W2156216923 hasConcept C198451711 @default.
• W2156216923 hasConcept C204787440 @default.
• W2156216923 hasConcept C27081682 @default.
• W2156216923 hasConcept C2777353892 @default.
• W2156216923 hasConcept C2777831278 @default.
• W2156216923 hasConcept C2780052408 @default.
• W2156216923 hasConcept C2780733359 @default.
• W2156216923 hasConcept C2780764818 @default.
• W2156216923 hasConcept C2781118164 @default.
• W2156216923 hasConcept C2910564767 @default.
• W2156216923 hasConcept C558461103 @default.
• W2156216923 hasConcept C71924100 @default.
• W2156216923 hasConceptScore W2156216923C118552586 @default.
• W2156216923 hasConceptScore W2156216923C126322002 @default.
• W2156216923 hasConceptScore W2156216923C142724271 @default.
• W2156216923 hasConceptScore W2156216923C168563851 @default.
• W2156216923 hasConceptScore W2156216923C1862650 @default.
• W2156216923 hasConceptScore W2156216923C198451711 @default.
• W2156216923 hasConceptScore W2156216923C204787440 @default.
• W2156216923 hasConceptScore W2156216923C27081682 @default.
• W2156216923 hasConceptScore W2156216923C2777353892 @default.
• W2156216923 hasConceptScore W2156216923C2777831278 @default.
• W2156216923 hasConceptScore W2156216923C2780052408 @default.
• W2156216923 hasConceptScore W2156216923C2780733359 @default.
• W2156216923 hasConceptScore W2156216923C2780764818 @default.
• W2156216923 hasConceptScore W2156216923C2781118164 @default.
• W2156216923 hasConceptScore W2156216923C2910564767 @default.
• W2156216923 hasConceptScore W2156216923C558461103 @default.
• W2156216923 hasConceptScore W2156216923C71924100 @default.
• W2156216923 hasIssue "3" @default.
• W2156216923 hasLocation W21562169231 @default.
• W2156216923 hasLocation W21562169232 @default.
• W2156216923 hasLocation W21562169233 @default.
• W2156216923 hasLocation W21562169234 @default.
• W2156216923 hasOpenAccess W2156216923 @default.

• next